Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a report released on Wednesday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

EGRX stock opened at $0.55 on Wednesday. The firm has a 50 day moving average of $0.69 and a 200-day moving average of $2.78. Eagle Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $6.81.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Creative Planning bought a new stake in Eagle Pharmaceuticals during the third quarter valued at $59,000. Mackenzie Financial Corp bought a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter valued at about $60,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Eagle Pharmaceuticals during the second quarter worth about $65,000. Fidelis Capital Partners LLC bought a new position in shares of Eagle Pharmaceuticals in the second quarter worth approximately $71,000. Finally, Vanguard Personalized Indexing Management LLC purchased a new stake in Eagle Pharmaceuticals in the second quarter valued at approximately $76,000. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.